Evidence map›Paper›PMID 42761148›Full record

SynthesisFrontiers in cellular and infection microbiology2026

Effects of gut microbiota-targeted interventions on pain, physical function, and inflammatory biomarkers in osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.

Tao Li, Juncheng Long, Yazhong Zhang, HongMei Luo, JianPing Yu

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tao Li *The Affiliated Hospital of Jiangxi University of Chinese Medicine Rheumatology Department, Nanchang, Jiangxi, China.
Juncheng Long *Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, China.
Yazhong ZhangWuzhou Hospital of Traditional Chinese Medicine Department of Traumatic Orthopedics, Wuzhou, Guangxi, China.
HongMei LuoThe Affiliated Hospital of Jiangxi University of Chinese Medicine Rheumatology Department, Nanchang, Jiangxi, China.
JianPing YuThe Affiliated Hospital of Jiangxi University of Chinese Medicine Rheumatology Department, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gut microbiota dysbiosis has been implicated in osteoarthritis (OA) through the gut-joint axis, but the clinical efficacy of gut microbiota-targeted interventions remains unclear. This systematic review and meta-analysis evaluated the effects of these interventions on clinical outcomes and inflammatory biomarkers in OA. Methods: PubMed, Embase, Web of Science, CNKI, and Wanfang were searched from inception to 20 January 2026 for randomized controlled trials (RCTs) of probiotics, prebiotics, synbiotics, or dietary modification in adults with OA. Primary outcomes were visual analog scale (VAS) pain, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, WOMAC function, and WOMAC total score; secondary outcomes included WOMAC stiffness, body weight, knee flexion angle, cartilage oligomeric matrix protein (COMP), high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), interleukin (IL)-1β, and IL-6. Standardized mean differences (SMDs) with 95% CIs were pooled using random-effects models; risk of bias was assessed with RoB 2.0. Subgroup analyses, univariable meta-regression, trial sequential analysis (TSA), and GRADE were used to grade certainty. Results: Eighteen RCTs (2,080 participants) were included. Interventions reduced VAS pain (SMD = -0.66, 95% CI: -1.27 to -0.06, Conclusion: Gut microbiota-targeted interventions, particularly probiotics, may improve pain, physical function, and systemic inflammation in OA. The evidence is compatible with symptomatic benefit but does not support cartilage protection or disease modification. Because certainty ranges from high to very low and information accrual is incomplete for most outcomes, these findings are provisional pending larger standardized RCTs. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/home, identifier CRD42023472181.

Indexed as

Gastrointestinal MicrobiomeOsteoarthritisPainBiomarkersCartilage Oligomeric Matrix ProteinDysbiosisHumansInflammationInterleukin-1betaPrebioticsProbioticsRandomized Controlled Trials as TopicSynbioticsTreatment OutcomeBiomarkersCartilage Oligomeric Matrix ProteinInterleukin-1betaPrebioticsgut-joint axisgut microbiotameta-analysisosteoarthritisprebioticsprobioticssystematic review

Identifiers

PMID42761148
PMCPMC13585646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.